Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

pembrolizumab 1266 Specimen Handling 927 Magnetic Resonance Spectroscopy 835 Carboplatin 825 Cyclophosphamide 804 Cisplatin 726 Nivolumab 666 Paclitaxel 630 Radiotherapy 609 Gemcitabine 571 Biopsy 561 Bevacizumab 481 Dexamethasone 439 fludarabine 409 Docetaxel 377 venetoclax 368 Oxaliplatin 364 Fluorouracil 356 Capecitabine 355 atezolizumab 351 durvalumab 334 Rituximab 332 Drug Therapy 325 Doxorubicin 317 Radiosurgery 315 Blood Specimen Collection 310 Standard of Care 310 Pemetrexed 305 Ipilimumab 297 Radiation 287

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

DLL3 protein, human × 1 year × Clear all

NCT06893783 2026-04-13

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡